LEAD PLAINTIFF DEADLINE IS MARCH 23, 2020
NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Geron Corporation (“Geron” or the “Company”) (GERN) common stock between March 19, 2018 and September 26, 2018, inclusive (the “Class Period”).
All investors who purchased shares of Geron Corporation and incurred losses are urged to contact the firm immediately at email@example.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information and join the action on our website, www.whafh.com.
If you have incurred losses in the shares of Geron Corporation, you may, no later than March 23, 2020, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Geron Corporation.
On March 27, 2018, STAT published a report revealing that the Company’s recent stock performance was due to “flimsy” claims in connection to the efficacy of imetelstat, Geron’s experimental myelofibrosis treatment. STAT stated that the available data for imetelstat undercuts Geron’s representations as to the drug’s efficacy.
On this news, Geron’s share price fell $1.75, or over 29%, over two consecutive trading sessions to close at $4.23 per share on March 27, 2018, thereby injuring investors.
Subsequently, on September 27, 2018, Geron disclosed its Phase 2 study results for imetelstat failed to meet its primary efficacy endpoints. On this news, Geron’s share price fell $3.92, or over 62%, to close at $2.31 per share on September 27, 2018.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at firstname.lastname@example.org, or visit our website at www.whafh.com to join this action.
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: email@example.com, firstname.lastname@example.org or email@example.com
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.